Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions
- PMID: 25751499
- PMCID: PMC6426450
- DOI: 10.1097/CJI.0000000000000065
Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions
Abstract
Osteosarcoma is the most common bone cancer in children and adolescents. Although 70% of patients with localized disease are cured with chemotherapy and surgical resection, patients with metastatic osteosarcoma are typically refractory to treatment. Numerous lines of evidence suggest that cytotoxic T lymphocytes (CTLs) limit the development of metastatic osteosarcoma. We have investigated the role of PD-1, an inhibitory TNFR family protein expressed on CTLs, in limiting the efficacy of immune-mediated control of metastatic osteosarcoma. We show that human metastatic, but not primary, osteosarcoma tumors express a ligand for PD-1 (PD-L1) and that tumor-infiltrating CTLs express PD-1, suggesting this pathway may limit CTLs control of metastatic osteosarcoma in patients. PD-L1 is also expressed on the K7M2 osteosarcoma tumor cell line that establishes metastases in mice, and PD-1 is expressed on tumor-infiltrating CTLs during disease progression. Blockade of PD-1/PD-L1 interactions dramatically improves the function of osteosarcoma-reactive CTLs in vitro and in vivo, and results in decreased tumor burden and increased survival in the K7M2 mouse model of metastatic osteosarcoma. Our results suggest that blockade of PD-1/PD-L1 interactions in patients with metastatic osteosarcoma should be pursued as a therapeutic strategy.
Conflict of interest statement
CONFLICTS OF INTEREST/ FINANCIAL DISCLOSURES
All authors have declared there are no flnancial conflicts of interest with regard to this work.
Figures
Similar articles
-
Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.Breast Cancer Res. 2016 May 11;18(1):50. doi: 10.1186/s13058-016-0708-2. Breast Cancer Res. 2016. PMID: 27169467 Free PMC article.
-
PD-L1 and IDO1 expression and tumor-infiltrating lymphocytes in osteosarcoma patients: comparative study of primary and metastatic lesions.J Cancer Res Clin Oncol. 2020 Oct;146(10):2607-2620. doi: 10.1007/s00432-020-03242-6. Epub 2020 May 9. J Cancer Res Clin Oncol. 2020. PMID: 32388585
-
Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy.Cancer Immunol Immunother. 2017 Jan;66(1):119-128. doi: 10.1007/s00262-016-1925-3. Epub 2016 Nov 16. Cancer Immunol Immunother. 2017. PMID: 27853827 Free PMC article.
-
Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer.Med Mol Morphol. 2017 Dec;50(4):185-194. doi: 10.1007/s00795-017-0170-y. Epub 2017 Sep 21. Med Mol Morphol. 2017. PMID: 28936553 Review.
-
PD-L1 Distribution and Perspective for Cancer Immunotherapy-Blockade, Knockdown, or Inhibition.Front Immunol. 2019 Aug 27;10:2022. doi: 10.3389/fimmu.2019.02022. eCollection 2019. Front Immunol. 2019. PMID: 31507611 Free PMC article. Review.
Cited by
-
Spatial multiplexed immunofluorescence analysis reveals coordinated cellular networks associated with overall survival in metastatic osteosarcoma.Bone Res. 2024 Sep 27;12(1):55. doi: 10.1038/s41413-024-00359-z. Bone Res. 2024. PMID: 39333065 Free PMC article.
-
Case report: pathological complete response after S-1/oxaliplatin regimen combined with trastuzumab and tislelizumab in patients with locally advanced gastric cancer.Front Oncol. 2024 Sep 5;14:1425572. doi: 10.3389/fonc.2024.1425572. eCollection 2024. Front Oncol. 2024. PMID: 39301541 Free PMC article.
-
PAK4 Is Involved in the Stabilization of PD-L1 and the Resistance to Doxorubicin in Osteosarcoma and Predicts the Survival of Diagnosed Patients.Cells. 2024 Aug 28;13(17):1444. doi: 10.3390/cells13171444. Cells. 2024. PMID: 39273017 Free PMC article.
-
Advances on immunotherapy for osteosarcoma.Mol Cancer. 2024 Sep 9;23(1):192. doi: 10.1186/s12943-024-02105-9. Mol Cancer. 2024. PMID: 39245737 Free PMC article. Review.
-
Checkpoint Immunotherapy in Pediatric Oncology: Will We Say Checkmate Soon?Vaccines (Basel). 2023 Dec 12;11(12):1843. doi: 10.3390/vaccines11121843. Vaccines (Basel). 2023. PMID: 38140246 Free PMC article. Review.
References
-
- Gill J, Ahluwalia MK, Geller D, et al. New targets and approaches in osteosarcoma. Pharmacol Ther 2013;137:89–99. - PubMed
-
- Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res 2009;152:3–13. - PubMed
-
- Bielack SS, Kempf-Bielack B, Heise U, et al. Combined modality treatment for osteosarcoma occurring as a second malignant disease. Cooperative German-Austrian-Swiss Osteo- sarcoma Study Group. J Clin Oncol 1999;17:1164. - PubMed
-
- Wang W, Wang J, Song H, et al. Cytotoxic T-lymphocyte antigen-4 + 49G/A polymorphism is associated with increased risk of osteosarcoma. Genet Test Mol Biomarkers 2011;15:503–506. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials